The National Agency for Food and Drug Administration and Control has recalled a batch of Amoxivue (Amoxicillin) 500mg capsules after tests showed low levels of the active ingredient. The affected batch, number 322584, was made by Sparsh Bio-Tech Pvt. Ltd in October 2023 and expires in October 2026.
NAFDAC said samples taken from facilities in Sokoto and Plateau State were tested with High-Performance Liquid Chromatography and Fourier Transform Infrared Spectroscopy, revealing the active ingredient content was only 26.3 percent.
Also Read: First Batch Of Nigerians Arrive Abuja From Sudan
The product also failed weight variation and infrared absorption spectrum tests, confirming it as substandard. Amoxivue is used to treat bacterial infections such as respiratory, ear, sinus, urinary tract, skin and soft tissue infections.
The agency warned that using the capsules could cause treatment failure, antibiotic resistance and other health risks, and urged the public to report suspicious medicines to the nearest NAFDAC office, by calling 0800-162-3322, or emailing [email protected]
Leave feedback about this
You must be logged in to post a comment.